Literature DB >> 9219512

Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.

S R Wedge1, J K Porteous, E S Newlands.   

Abstract

The purpose of the present study was to examine the effect of O6-benzylguanine (O6-BG) on the antitumour activity and toxicity of 8-carbamoyl-3-methylimidazo [5, 1-d]-1,2,3,5-tetrazine-4(3H)-one (temozolomide) in a human malignant melanoma xenograft model following single and multiple administration of the combination. O6-BG irreversibly inactivates the DNA-repair protein O6-alkylguanine-DNA alkyltransferase (AGT), which confers resistance to temozolomide. Preadministration of O6-BG (35 mg/kg, i.p.) 1 h prior to temozolomide (i.p.) was examined using single and daily x5 dosing regimens in athymic mice bearing subcutaneous A375P xenografts. The AGT activity of A375P tumors was 95 +/- 8 fmol/mg protein (mean +/- SE, n = 4). O6-BG alone completely suppressed xenograft AGT activity within 1 h of administration but had no effect upon tumor growth. O6-BG did not significantly increase the tumor growth delay induced by a single 200-mg/ kg dose of temozolomide (P > 0.05, two-tailed Mann-Whitney test) but did increase the associated mean body weight loss (P < 0.025). In contrast, when the same dose of temozolomide was divided into five equal fractions (40 mg/kg) and given with O6-BG on 5 consecutive days, a comparable increase in toxicity was accompanied by a very significant increase in tumor growth delay (P < 0.0025), equivalent to that produced by a 3-fold greater dose of temozolomide alone. O6-BG with temozolomide also produced a greater antitumour effect than an equitoxic dose of temozolomide alone on this schedule (P < 0.005). These data indicate that the enhancement of temozolomide antitumour activity by O6-BG preadministration is dependent upon the schedule of drug administration, with multiple dosing of O6-BG + temozolomide producing the greatest effect. The results also suggest that prolonged administration of the combination can lead to an increase in the therapeutic index of temozolomide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219512     DOI: 10.1007/s002800050657

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

2.  Phase II trial of temozolomide in children with recurrent high-grade glioma.

Authors:  A Ruggiero; G Cefalo; M L Garré; M Massimino; C Colosimo; G Attinà; I Lazzareschi; P Maurizi; V Ridola; G Mazzarella; M Caldarelli; C Di Rocco; E Madon; M E Abate; A Clerico; A Sandri; R Riccardi
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

Review 3.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

4.  Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.

Authors:  Mingzhong Zheng; Dora Bocangel; Rajagopal Ramesh; Suhendan Ekmekcioglu; Nancy Poindexter; Elizabeth A Grimm; Sunil Chada
Journal:  Mol Cancer Ther       Date:  2008-12-03       Impact factor: 6.261

5.  Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.

Authors:  W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

6.  Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Amy Walker; Henry S Friedman
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

7.  Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program.

Authors:  Stephen T Keir; John M Maris; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Jianrong Wu; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-01-17       Impact factor: 3.167

Review 8.  Chemotherapy in the management of advanced cutaneous malignant melanoma.

Authors:  Jason J Luke; Gary K Schwartz
Journal:  Clin Dermatol       Date:  2013 May-Jun       Impact factor: 3.541

Review 9.  Recent advances in combined modality therapy.

Authors:  Michelle L Mierzwa; Mukesh K Nyati; Meredith A Morgan; Theodore S Lawrence
Journal:  Oncologist       Date:  2010

Review 10.  Role of Polymeric Local Drug Delivery in Multimodal Treatment of Malignant Glioma: A Review.

Authors:  Yuan-Yun Tseng; Tai-Yuan Chen; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.